hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
. At the moment a particle leaves the control volume, its age is the total time that the particle has spent inside the control volume, which is known as its residence time. The frequency of occurrence of the age
Maisie Mosco (7 December 1924 – 31 October 2011) wrote 16 novels between 1979 and 1998. These include the 'Almonds and Raisins' series (Almonds & Raisins, Scattered Seed, Children's Children, Out of the Ashes, and New Beginnings), about a Jewish family who around 1900 fled anti-Jewish pogroms in the Russian Empire and emigrated to north Manchester in England. These books contained elements of her own family history and were dramatized for BBC Radio 4. Michael Moritz (b. 1954) billionaire venture capitalist, philanthropist, author, journalist; works for Sequoia Capital, wrote history of Apple Inc., The Little Kingdom, and Going for Broke: Lee Iacocca's Battle to Save Chrysler; was writer at Time magazine and member of board of directors of Google; founded Technologic Partners; named as the No. 1 venture capitalist on the Forbes Midas List; appointed Knight Commander of the Order of the British Empire (KBE). Claus Moser, Baron Moser, (24 November 1922 – 4 September 2015) was a British statistician, scholar and author who made major contributions in both academia and the Civil Service.
Rodney Smith Markin (born 1956), is an American pathologist and authority in the field of laboratory automation. In 1993, he designed and created one of the world's first automated clinical laboratory specimen, device and analyzer management systems. In the mid-1990s, he chaired a standards group called the Clinical Testing Automation Standards Steering Committee (CTASSC) of the American Association for Clinical Chemistry, which later evolved into an area committee of the Clinical and Laboratory Standards Institute. Markin serves as the Vice President for Business Development and practices pathology at Nebraska Medicine, is associate vice chancellor for business development for the University of Nebraska Medical Center, and executive director of the UNeTech Institute of the University of Nebraska Medical Center and the University of Nebraska Omaha. He serves as both the David T. Purtilo Professor in the Department of Pathology and Microbiology in UNMC's College of Medicine as well as the Executive Director of the UNeTech Institute. Prior to his current position, he was the chief operating officier of the University of Nebraska system, the chief technology officer at UNMC, interim dean of the UNMC College of Medicine, board chairman and president and CEO of the Nebraska Medicine clinical practice plan (fka UNMC Physicians), an academic medical practice which includes more than 750 physicians, and has held several other administrative and academic positions at the University of Nebraska Medical Center.
These results highlight the clinical translation of α-amanitin’s cell-cycle-independent mechanism, which effectively targets both proliferating tumor cells and quiescent cancer stem cells. The ATAC platform is also advancing into solid tumors. TROP2-targeted conjugates based on the hRS7 antibody achieved complete tumor eradication in patient-derived xenograft models of pancreatic cancer and triple-negative breast cancer, outperforming the approved ADC sacituzumab govitecan. In January 2026, Takeda initiated a Phase I/II clinical trial of an ATAC candidate for solid tumors.
Sources: en.wikipedia.org
Protein import into mitochondria Hundreds of proteins encoded by the nucleus are required for mitochondrial metabolism, growth, division, and partitioning to daughter cells, and all of these proteins must be imported into the organelle. Translocase of the outer membrane (TOM) and translocase of the inner membrane (TIM) mediate the import of proteins into the mitochondrion. The translocase of the outer membrane (TOM) sorts proteins via several mechanisms either directly to the outer membrane, the intermembrane space, or the translocase of the inner membrane (TIM). Then, generally, the TIM23 machinery mediates protein translocation into the matrix and the TIM22 machinery mediates insertion into the inner membrane. Fatty acids import into mitochondria (Carnitine Shuttle System) Carnitine-acylcarnitine translocase (CACT) catalyzes both unidirectional transport of carnitine and carnitine/acylcarnitine exchange in the inner mitochondrial membrane, allowing the import of long-chain fatty acids into the mitochondria where they are oxidized by the β-oxidation pathway. The mitochondrial membrane is impermeable to long-chain fatty acids, hence the need for this translocation.
== Necessary examinations during treatment == Complete blood counts should be obtained before starting chemotherapy and in short intervals afterwards. Platelet counts should be done at the time of expected nadir (lowest number of platelets) and at least until remission starts (platelet counts greater than 50,000). The patients should be watched for signs of allergy, fluid retention and anemia during and after therapy with Neumega. Preexisting ascites and pericardial effusions should be monitored closely for signs of worsening.
Another case was that of Ismil bin Kadar, who was initially sentenced to death for a 2005 robbery-murder case in Boon Lay, but eventually acquitted of the crime as the Court of Appeal found that based on the evidence, Ismil was not involved in the case and that it was solely his younger brother Muhammad bin Kadar who was responsible for the robbery and murder; Muhammad was subsequently executed in April 2015. Successful clemency applications are thought to be even rarer. Since 1965, the presidential clemency has been granted seven times to death row inmates, whose sentences were all commuted to life imprisonment (not counting the clemency pleas of the underaged offenders serving TPP). The most recent case was in August 2025, when convicted drug trafficker Tristan Tan Yi Rui was granted clemency by President Tharman Shanmugaratnam, who commuted Tan's death sentence to life imprisonment. Prior to Tan's pardon, the last presidential clemency to be granted was in April 1998, when President Ong Teng Cheong pardoned a 19-year-old death row inmate and convicted murderer Mathavakannan Kalimuthu, commuting his death sentence to life imprisonment. Previously, other than the Court of Appeal, offenders were allowed to file criminal or civil appeals to the Privy Council in London, where the judges could hear their appeals once they exhausted all avenues of appeal in Singapore. This avenue of appeal was fully abolished for all criminal and civil matters in April 1994. One case in which an appeal to the Privy Council was successful was the case of murderer Mohamed Yasin bin Hussin.
Sources: en.wikipedia.org
He recalls that Boris Johnson struggled with scientific concepts, and that after a five-hour meeting with him, after the Prime Minister had returned from a "Battle of Britain memorial service and was distressed by seeing everyone separated and in masks", he "looked broken – his head in hands a lot." He quotes the PM saying "We are too shit to get our act together". He also recalls that Chief Medical Officer Chris Whitty had concerns about the "indirect harms" of lockdown. 21 November Four bodies are found by North Wales Police in the search for teenage boys missing for two days, after their car appeared to have left the road near Tremadog. A coroner's inquest later finds they drowned, after the vehicle overturned and became partially submerged in water. Chancellor Jeremy Hunt announces an increase in the National Living Wage to £11.44 from April 2024; with the increase also encompassing those aged 21 and 22 for the first time. 22 November Lady Justice Thirlwall formally opens the public inquiry into the activities of serial killer Lucy Letby. Jeremy Hunt delivers the November 2023 United Kingdom autumn statement. 23 November More than 50 firefighters tackle a major blaze at the Station Hill development in Reading. One person is lifted by crane from the roof of a building, and two people are treated in hospital for smoke inhalation. Office for National Statistics data suggests that in 2022, net migration—the difference between the number of people arriving in the UK and leaving the UK—was 745,000, something the UK government describes as too high.
1333: Thomasia de Mattio, Italian physician, mentioned in Pope Sixtus IV edict regarding physicians and surgeons. fl. 1335: Polisena da Troya, licensed Neapolitan surgeon. d. 1366: Jeanne d'Ausshure, French surgeon. fl. 1374: Floreta La-Noga, Aragonese physician. fl. 1376: Virdimura of Catania, Jewish-Sicilian physician. fl. 1380: Bellayne Gallipapa, Zaragoza, Aragonese-Jewish physician. fl. 1384: Dolcich Gallipapa, Lleida, Catalan-Jewish physician. fl. 1384: Juana Sarrovia, Barcelona, Catalan physician. fl. 1387: Na Pla Gallipapa, Zaragoza, Aragonese-Jewish physician. late 13th century: Margherita di Napoli, Napolitan oculist active in Frankfurt-am-Main. fl. 1390: Dorotea Bucca, Italian professor of medicine. 1386–1408: Maesta Antonia, Florentine physician. 14th century: Abella, Italian physician. 14th century: Mercuriade, Italian physician and surgeon. fl. 1400: Antonia Daniello, Florentine-Jewish physician. fl. 13th century: Brunetta de Siena, Italian-Jewish physician. fl. 13th century: Caterina of Florence, Florentine physician. fl. 1411: Peretta Peronne, also called Perretta Petone, French surgeon. fl. 1415: Constance Calenda, Italian surgeon specializing in diseases of the eye. fl. 1438: Jeanne de Cusey, French barber-surgeon. fl. 1460: Marguerite Saluzzi, Napolitan licensed herbalist physician. fl. 1479: Guillemette du Luys, French royal surgeon. d. 1498: Gentile Budrioli (or Gentile Cimieri), Italian astrologer and herbalist. 15th century: Clarice di Durisio, Italian physician. 15th century Francesca, muller de Berenguer Satorra, Catalan physician. c.
==== Hawaii ==== In Hawaii, where cuisine is heavily influenced by Asian cultures, glass noodles are known locally as long rice, supposedly because the process of making the noodles involves extruding the starch through a potato ricer. They are used most often in chicken long rice, a dish of glass noodles in chicken broth that is often served at luaus.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.